Lataa...
Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
Secondary hyperparathyroidism (SHPT) is common in patients receiving maintenance hemodialysis and is associated with adverse outcomes. Currently, SHPT is managed by reducing circulating levels of phosphate with oral binders and parathyroid hormone (PTH) with vitamin D analogs and/or the calcimimetic...
Tallennettuna:
| Julkaisussa: | Int J Nephrol Renovasc Dis |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5804266/ https://ncbi.nlm.nih.gov/pubmed/29440923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S128252 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|